# ENZA-p (NCT04419402)

> Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04419402
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Conditions: Metastatic Castration-Resistant Prostate Cancer
- Interventions: Lu-PSMA; Enzalutamide
- Enrollment: 162
- Primary outcome: Prostate Specific Antigen (PSA) Progression-Free Survival

## Commentary we found

- X threads: 71
- YouTube: 21
- Podcasts: 9
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=enza-p-nct04419402

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04419402", "email": "<work email>"}; the inbox owner confirms by the emailed link.